Safety and Efficacy Demonstrated in 3 Placebo-controlled Clinical Trials
Solo 1, solo 2
Evaluated dupilumab as monotherapy for 16 weeks
LIBERTY AD CHRONOS
Long-term evaluation of dupilumab in combination with TCS
Menu
New and Emerging Therapeutic Options 
Dupilumab Phase 3 Clinical Trials
Click for data
Efficacy of DupilumabClick for data
Safety of Dupilumab